Alcon Site Directory

Search Results for: netter 1

Efficacy and safety of 177 Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study

https://www.adacap.com/publications/efficacy-and-safety-of-177-lu%e2%80%91dotatate-in-patients-with-advanced-pancreatic-neuroendocrine-tumours-data-from-the-netter-r-international-retrospective-study/

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

https://www.adacap.com/publications/%c2%b9%e2%81%b7%e2%81%b7lu-dotatate-plus-long-acting-octreotide-versus-high%e2%80%91dose-long-acting-octreotide-in-patients-with-midgut-neuroendocrine-tumours-netter-1-final-overall-survival-and-lo/

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

https://www.adacap.com/novartis-177lu-psma-617-significantly-improves-overall-survival-and-radiographic-progression-free-survival-for-men-with-metastatic-castration-resistant-prostate-cancer-in-phase-iii-vision-study/

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-DOTATATE: an analysis of the NETTER-1 study

https://www.adacap.com/publications/impact-of-liver-tumour-burden-alkaline-phosphatase-elevation-and-target-lesion-size-on-treatment-outcomes-with-177lu-dotatate-an-analysis-of-the-netter-1-study/

Netter-1

https://www.adacap.com/clinical_trials/netter-1/

Impact of Liver Tumor Burden on Therapeutic Effect of 177Lu-DOTATATE Treatment in NETTER-1

https://www.adacap.com/publications/impact-of-liver-tumor-burden-on-therapeutic-effect-of-177lu-dotatate-treatment-in-netter-1/

EANM 2018: NETTER-1 Study Abstracts

https://www.adacap.com/publications/eanm-2018-netter-1-study-abstracts/

Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors

https://www.adacap.com/publications/clinical-outcomes-in-patients-with-baseline-renal-dysfunction-in-the-netter-1-study-177lu-dotatate-lutathera-vs-high-dose-octreotide-in-progressive-midgut-neuroendocrine-tumors/

First Update on Overall Survival, Progression-free Survival, and Time-to-deterioration of Health-related Quality of Life from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors

https://www.adacap.com/publications/first-update-on-overall-survival-progression-free-survival-and-time-to-deterioration-of-health-related-quality-of-life-from-the-netter-1-study-177lu-dotatate-lutathera-vs-high-dose-octreoti/

Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

https://www.adacap.com/publications/overall-survival-progression-free-survival-and-quality-of-life-updates-from-the-netter-1-study-177lu-dotatate-lutathera-vs-high-dose-octreotide-in-progressive-midgut-neuroendocrine-tumors/